GlassScriptPhysician profile
Matthew Kenneth Redd
NPI 1154642791
$8,103.63
in general payments reported to CMS, 2019-2025
34 companies · $1,510 in 2025
The $1,510 reported for 2025 was more than what 90% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $973 · 2020: $576 · 2021: $1,269 · 2022: $989 · 2023: $1,515 · 2024: $1,272 · 2025: $1,510.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,297.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,296.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,607.58 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $1,470.96 | 2019-2025 | Entyvio |
| Janssen Biotech, INC. | $888.35 | 2019-2025 | Tremfya, Stelara |
| Pfizer INC. | $608.36 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $439.96 | 2019-2023 | Xifaxan, Relistor, Trulance |
| Regeneron Healthcare Solutions, INC. | $402.22 | 2022-2025 | Dupixent |
| Celgene Corporation | $192.94 | 2021-2024 | Zeposia |
| Qol Medical, LLC | $179.94 | 2021-2024 | Sucraid, Sucraid |
| Nestle Healthcare Nutrition INC. | $159.31 | 2021-2023 | |
| Erbe USA INC | $132.55 | 2019 | |
| Gilead Sciences, INC. | $116.25 | 2019-2024 | |
| Allergan, INC. | $115.07 | 2019-2020 | |
| Redhill Biopharma INC. | $102.60 | 2021-2022 | |
| Ardelyx, INC. | $96.00 | 2024-2025 | Ibsrela |
| Genzyme Corporation | $89.41 | 2024-2025 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ferring Pharmaceuticals INC. | $71.43 | 2019-2023 | Rebyota |
| Braintree Laboratories, INC. | $45.65 | 2020-2023 | Sutab |
| Merck Sharp & Dohme LLC | $40.47 | 2019-2021 | |
| Intercept Pharmaceuticals, INC. | $40.24 | 2020 | |
| Fresenius Kabi USA, LLC | $37.14 | 2023 | Idacio |
| Aimmune Therapeutics, INC. | $36.60 | 2024 | |
| Organon LLC | $29.91 | 2021-2022 | |
| Capsovision, INC. | $25.07 | 2025 | Capsocam Plus |
| Celltrion USA INC. | $22.75 | 2025 | Vegzelma |
| Laborie Medical Technologies Corp. | $17.59 | 2024 | Solar Uroflow System |
| Novo Nordisk INC | $16.91 | 2025 | Wegovy |
| Biocon Biologics INC | $16.65 | 2025 | Yesintek |
| Currax Pharmaceuticals LLC | $16.37 | 2023 | Contrave |
| Evoke Pharma, INC. | $16.30 | 2022 | |
| Boston Scientific Corporation | $15.91 | 2023 | Compliance Endokit |
| Daiichi Sankyo INC. | $14.37 | 2022 | |
| Lucid Diagnostics INC. | $13.42 | 2023 | |
| Alexion Pharmaceuticals, INC. | $12.86 | 2019 | |
| Phathom Pharmaceuticals, INC. | $12.49 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Redd listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.